Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.

Cancer - 15 Sept 2007

Jatoi Aminah, Dakhil Shaker R, Nguyen Phuong L, Sloan Jeff A, Kugler John W, Rowland Kendrith M, Soori Gamini S, Wender Donald B, Fitch Tom R, Novotny Paul J, Loprinzi Charles L

Abstract excerpt

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome. The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton TNF receptor linked to the Fc portion of human immunoglobulin [Ig] G1) could palliate this syndrome. METHODS: A total of 63...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Appetite
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etanercept

Share to Immunologic Factors

Share to Palliative Care

Share to Receptors, Tumor Necrosis Factor

Share to Weight Gain

Share to Weight Loss

Source

Identifiers

PMID: 17674351
DOI: 10.1002/cncr.22944

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.PMID 17674351Read ↗

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).Semantic proximity Read ↗

The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer.Semantic proximity Read ↗

Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma.Semantic proximity Read ↗

Investigating the orexigenic potential of olanzapine in cancer patients (OLANZAPRIZ): A Systematic ReviewSemantic proximity Read ↗

Body Mass Index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancerSemantic proximity Read ↗

Body Mass Index and patient-reported measures of function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancerSemantic proximity Read ↗

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issuesSemantic proximity Read ↗

A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese PersonsSemantic proximity Read ↗

Separating anorexia -dependent and -independent effects in cancer cachexiaSemantic proximity Read ↗

Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.Semantic proximity Read ↗

Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.